The Novartis Access scheme – first announced last month – covers drugs to treat cardiovascular diseases, diabetes, respiratory illnesses and breast cancer and officially gets underway in Kenya ...

Novartis' programme providing free access to its spinal muscular atrophy (SMA) gene therapy Zolgensma is being scaled back to a dozen countries worldwide, according to the company. First ...

The National Football League has signed its first-ever pharmaceutical partner in a multi-year deal with Switzerland-based ...

Baptised “Novartis Access” the affordable drugs portfolio is targeted at chronic diseases like diabetes, respiratory illnesses, cardiovascular diseases and breast cancer. The choice was made ...

Swiss pharmaceutical company Novartis envisions a world where access to healthcare is not a privilege but a fundamental human right, and this vision drives its global health initiatives.

The deal gives Novartis access to abelacimab, which is currently in phase 3 development for the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF). Approximately 1.5 ...

This article was coproduced with Kody Kester. Since last October, Novartis' shares have lagged the S&P 500 index. The pharmaceutical company's pipeline remains robust, which could translate into ...

The work is part of Novartis’ push to ensure patients can access and benefit from advances in the treatment of prostate cancer. Novartis, too, could profit from better access to care.

Novartis, however, argued that the program imposed ... Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.